Phase 2 endometriosis trial reaches recruitment milestone
apopescu@pmlive.com | June 15, 2026 | News story | Research and Development | Gesynta Pharma, endometriosis
Gesynta Pharma has announced that 50% of the target enrolment has been reached in its phase 2 NOVA trial evaluating vipoglanstat, an investigational treatment for endometriosis. Top-line results are expected in 2027.
The randomised, double-blind, placebo-controlled study aims to recruit 190 women across Europe and is assessing the efficacy and safety of two dose levels of vipoglanstat.
Endometriosis affects more than 10% of women of reproductive age and can cause severe pelvic pain, painful periods, gastrointestinal symptoms and infertility. Current treatment options are largely limited to pain relief, hormonal therapies and surgery.
Vipoglanstat is being developed as a non-hormonal, non-opioid treatment. The oral therapy targets microsomal prostaglandin E synthase-1 (mPGES-1), an enzyme involved in the production of prostaglandin E2, a key inflammatory mediator associated with endometriotic lesions.
Eva Johnsson, Chief Medical Officer and Vice President Clinical Development at Gesynta Pharma, said reaching the recruitment milestone ahead of schedule reflected strong interest from both investigators and participants.
The Swedish company said the study is designed to generate data to support planning of a future phase 3 programme.
Previous clinical studies have demonstrated a favourable safety and tolerability profile, while preclinical research suggested the therapy could reduce both pain-related behaviours and endometriotic lesion burden.
Patric Stenberg, Chief Executive Officer of Gesynta Pharma, said the programme represented an important step towards addressing a major unmet need in women’s health.
“The NOVA trial is a significant advancement in a field with few ongoing clinical trials, and a key step toward establishing a strong foundation for a future Phase 3 program for vipoglanstat,” he added.
Endometriosis remains one of the most common chronic inflammatory conditions affecting women, yet treatment innovation in the field has been relatively limited.
Related Content
Endometriosis study begins recruitment in UK hospitals
Cyclana Bio has recruited the first patients into a 500-participant observational study investigating the biological …
Gesynta Pharma doses first patient in endometriosis phase 2 trial
Gesynta Pharma has dosed the first patient in its phase 2 clinical proof-of-concept trial of …
EndoCyclic New Drug application approved by US FDA for endometriosis treatment
EndoCyclic Therapeutics’ Investigational New Drug (IND) application for its lead programme, ENDO-205, has been approved …
